

## REMARKS

Claims 1-15 are active in the present application.

Applicants have now submitted a substitute Sequence Listing and a corresponding computer-readable Sequence Listing. Contents of the paper copy of the substitute Sequence Listing and the computer-readable Sequence Listing are identical. Support for all the sequences listed in the substitute Sequence Listing can be found in the present application. No new matter is introduced by the submission of the substitute Sequence Listing and the computer-readable Sequence Listing.

Applicants submit that this application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
I:\atty\Twb\214595US-PR.wpd

**Marked-Up Copy**

Serial No: \_\_\_\_\_

Amendment Filed on: \_\_\_\_\_

10-2-01

**IN THE SPECIFICATION**

Page 8, beginning at line 22, please delete the paragraph and replace it with the following paragraph:

--(11) A subunit peptide originating from an oligomeric [peptide] protein having disulfide bonds within a subunit and between subunits, wherein

polyoxyalkyl polyether is bonded to a cysteine residue that is originally involved in formation of a disulfide bond between subunits of the oligomeric protein, among cysteine residues in the subunit peptide, and the subunit peptide has decreased antigenicity.--